Provided is a device for real-time measurement of bacteria. The device for real-time measurement of bacteria includes reaction portions, a support portion configured to support the reaction portions, a rotational shaft configured to transfer the support portion, and a sample supply portion configured to supply a sample to each of the reaction portions, and according to the device for real-time measurement of bacteria, bacteria may be measured in real time through the detection of ATP.

This disclosure provides a method of determining the viability of at least one cell via quantification of nicotinamide adenine dinucleotide (phosphate) (NAD(P)H), flavin adenine dinucleotide (FAD), and/or collagen. The method includes the steps of contacting the at least one cell with light having a wavelength of from 700 to 900 nm, using two photon excitation, or from 335 to 400 nm, using one photon excitation, to induce an optical response from the NAD(P)H, FAD, and/or collagen and measuring the optical response. The method also includes the step of quantifying one or more of an amount, spatial localization, and/or time-dependent response of the NAD(P)H, FAD, and/or collagen utilizing the optical response.

NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Analyte sensors include an electrode having a sensing layer disposed thereon, the sensing layer comprising a polymer and an enzyme composition distributed therein. The enzyme composition includes nicotinamide adenine dinucleotide phosphate (NAD(P)+) or derivative thereof; an NAD(P)+-dependent dehydrogenase; an NAD(P)H oxidoreductase; and an electron transfer agent comprising a transition metal complex.

The invention relates to the in vitro and in cellulo detection of the cofactors nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). Provided is a sensor molecule for fluorescence- or luminescence-based detection of a nicotinamide adenine dinucleotide analyte, in particular for detecting the concentrations of NAD.sup.+, NADP.sup.+ and/or the ratios of the concentrations of NAD.sup.+/NADH and NADP.sup.+/NADPH, the sensor comprising (i) a binding protein (BP) for the nicotinamide adenine dinucleotide analyte, the BP being derived from sepiapterin reductase (SPR; EC 1.1.1.153) (ii) an SPR ligand (SPR-L) capable of intramolecular binding to said BP in the presence of the oxidized form of said analyte; and (iii) at least one fluorophore.

Embodiments of the present disclosure relate to NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Also provided are methods for making the compositions and for detecting and/or measuring analytes with NADP-dependent oxidoreductase compositions.

Methods and formulations for diagnosing metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.

A preparation method and use of a BiOX/N-doped biochar nanocomposite, where X is I or Br is provided. The preparation method includes the following steps: step 1: preparation of an N-doped biochar; step 2: preparation of an acidified N-doped biochar; and step 3: preparation of the BiOX/N-doped biochar nanocomposite. In the present disclosure, a discarded crayfish shell, crab shell, or tofu residue is used as a raw material to prepare the BiOX/N-doped biochar nanocomposite, to realize the transformation of a renewable biological resource from waste into treasure. A photoelectric sensor is constructed based on the BiOX/N-doped biochar nanocomposite that can realize the detection of adenosine triphosphate (ATP) or Escherichia coli (E. coli).

Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.

Methods and formulations for diagnosing onocological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.

The present invention relates to the use of a reduced folate, such as 5-MTHF (5-methyltetrahydrofolate), optionally in combination with tetrahydrobiopterin (BH4) or precursors thereof, for preventing or treating disorders associated with a BH4 deficiency, or low BH4 bioavailability. Such disorders primarily include diseases which have vascular endothelial pathology, or effects on amino acid metabolism or neurotransmission, especially pregnancy related disorders such as pre-eclampsia.